In what is considered to be the biggest consolidation move in the generics industry, Pfizer is said to be in talks to merge its off-patent drugs business with Mylan in a stock deal, the Wall Street Journal (WSJ) reported on July 27, citing people familiar with the matter. The expiration of patents on some of its blockbuster drugs, and the subsequent entry of generics is the reason for the slower growth of Pfizer sales. The company also wants to focus more on innovative drugs and vaccines. Sandoz is the generic unit of Swiss drug maker Novartis. The company is also a part of India’s formulation business.
This news content is a computer generated summarized version of the original article and the authenticity of the original content has not been verified. Please click on the View Article button to refer to the actual content.